Irrespective of why this stock is and has been oversold for the past six months ( of course time lines on results can vary with bio companies), the business model is strong (9.4 mil in funds), hence management again needs to be commended on burn rate.
Ann: December 2016 Appendix 4C - Quarterly, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
